Neupogen 30 MU / ml. 30 MU / 0.5ml. 48 / 0.5ml Injection
PDF Leaflet Revision Date: 14 September 2012
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of neutropenia duration in chemotherapy patients.
Dosage (summary)
0.5 MU/kg/day subcutaneously; adjust based on ANC response.
Onset of Action / Duration
Onset: 24 hours, Duration: 1-7 days post-therapy.
Special Populations
- Renal impairment
- Hepatic impairment
- Paediatrics
- Geriatrics
Pregnancy & Breastfeeding
Not established; avoid in pregnancy and breastfeeding.
Key Drug Interactions
- Lithium may potentiate effects
- Avoid with myelosuppressive chemotherapy
Contraindications
- Known sensitivity
- Severe congenital neutropenia with abnormal cytogenetics
Common side effects
- Musculoskeletal pain
- Nausea
- Vomiting
- Fatigue
- Headache
Counselling Points
- Monitor for allergic reactions
- Report any bone pain
- Avoid in sickle cell disease
Serious warnings
- Hypersensitivity
- Pulmonary toxicity
- Sickle cell crises
Important Disclaimer
The Neupogen 30 MU / ml. 30 MU / 0.5ml. 48 / 0.5ml Injection professional information leaflet below is the property of Amgen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
